Point72 Asset Management
ICPT

Point72 Asset Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Point72 Asset Management’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-15,000
Closed -$1.51M – 1288
2018
Q4 		$1.51M Buy
15,000
+9,800
+188% +$1.02M 0.01% 757
2018
Q3 		$657K Buy
+5,200
New +$550K ﹤0.01% 907

Other funds holding ICPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Point72 Asset Management's ICPT Position: Q1 2023 in Review

Point72 Asset Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2023, closing a stake of 166,300 shares — an estimated $2.06M sold.

Point72 Asset Management first reported a position in ICPT in Q2 2014 and held it in 19 quarters. The position peaked at $72.5M in Q1 2019. 144 funds tracked by Wall St. Rank hold ICPT as of Q1 2023.

  • Point72 Asset Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Point72 Asset Management sold 166,300 Intercept Pharmaceuticals, Inc. shares in Q1 2023, an estimated $2.06M.
  • Point72 Asset Management first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2014 and held it in 19 quarters.
  • Point72 Asset Management's Intercept Pharmaceuticals, Inc. position peaked at $72.5M in Q1 2019.
  • 144 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2023.

Based on Point72 Asset Management's 13F filing for Q1 2023, filed 15 May 2023.